EVMN
Evommune, Inc.
$19.92
-3.72%
$745.2M
No data for this timeframe.
Vol
Market Cap$745.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders5 funds
Inst. Value$10.2M
Inst. Activity5 buys / 0 sells
Insider Activity0B / 5S
Insider Net $-$1.6M
SEC Reports9
Recent Activity
Jun 5, 2026
SEC
Gregory S. Moss, an officer of Evommune, filed a Form 144 on May 28, 2026, indicating intent to sell 14,223 shares of co
144 — Impact 5/10
Jun 4, 2026
SEC
Three top executives at Evommune (CEO, CFO, CLO) sold a combined $1.12M in open-market sales over a 5-day window, repres
CLUSTER — Impact 5/10
Jun 2, 2026
SEC
Director David E. Cohen filed a Form 144 notice of intent to sell 9,258 shares of Evommune (EVMN) common stock, with an
144 — Impact 3/10
Jun 2, 2026
Insider
KIRSCH ARTHUR S sold 15,673 shares
Director @ $0.00 ($0.00)
Jun 2, 2026
Insider
Cohen David E sold 15,673 shares
Director @ $0.00 ($0.00)
Jun 2, 2026
Insider
MCGRAW BENJAMIN F III sold 15,673 shares
Director @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — NEW
502,574 shares ($8.6M)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — NEW
62,704 shares ($1.1M)
Price Targets
$52.25
+162.3% upside
Strong Buy
Current $19.92
Low $50.00
Median $52.00
High $55.00
8 analysts
$50.00
$55.00
Analyst Ratings
7Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 11, 2026 | Morgan Stanley | MAINTAIN | Overweight → Overweight |
| Apr 10, 2026 | RBC Capital | REITERATE | Outperform → Outperform |
| Mar 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 18, 2026 | Clear Street | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.67 ▲ +2.2% | $-0.76 — $-0.61 | 8 | |
| Next Q | $-0.69 ▼ -4.9% | $-0.90 — $-0.18 | 92% YoY | 8 |
| Current FY | $-2.75 ▲ +14.4% | $-3.30 — $-2.09 | 76% YoY | 8 |
| Next FY | $-3.33 ▲ +1.0% | $-4.83 — $-2.48 | -21% YoY | 8 |
Latest Reports
BEARISH
144
5/10
Gregory S. Moss, an officer of Evommune, filed a Form 144 on May 28, 2026, indicating intent to sell 14,223 shares of co
Jun 5, 2026
BEARISH
CLUSTER
5/10
Three top executives at Evommune (CEO, CFO, CLO) sold a combined $1.12M in open-market sales over a 5-day window, repres
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $8.6M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.1M | NEW |
| TWO SIGMA INVESTMENTS, LP | $365.1K | NEW |
| MORGAN STANLEY | $142.9K | NEW |
| BANK OF AMERICA CORP | $50.3K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | KIRSCH ARTHUR | A | $0.00 |
| Jun 2, 2026 | Cohen David | A | $0.00 |
| Jun 2, 2026 | MCGRAW BENJAMIN | A | $0.00 |
| Jun 2, 2026 | Cohen David | SELL | $110.3K |
| Jun 1, 2026 | Patel Jeegar | M | $0.00 |
5 institutional holders with $10.2M total value (597,885 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, TWO. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 502,574 | $8.6M | 84.1% | NEW |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 62,704 | $1.1M | 10.5% | NEW |
| 3 | TWO SIGMA INVESTMENTS, LP | 21,324 | $365.1K | 3.6% | NEW |
| 4 | MORGAN STANLEY | 8,346 | $142.9K | 1.4% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 2,937 | $50.3K | 0.5% | NEW |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | NEW | — | 502,574 | — | $8.6M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 62,704 | — | $1.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 21,324 | — | $365.1K | 2025-Q4 |
| MORGAN STANLEY | NEW | — | 8,346 | — | $142.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 2,937 | — | $50.3K | 2025-Q4 |
10 unique insiders with 5 transactions. Net insider value: -$1.6M ($0.00 bought, $1.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | KIRSCH ARTHUR S | Director | A | 15,673 | $0.00 | $0.00 |
| Jun 2, 2026 | Cohen David E | Director | A | 15,673 | $0.00 | $0.00 |
| Jun 2, 2026 | MCGRAW BENJAMIN F III | Director | A | 15,673 | $0.00 | $0.00 |
| Jun 2, 2026 | Cohen David E | Director | SELL | 5,456 | $20.21 | $110.3K |
| Jun 1, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | M | 13,512 | $0.00 | $0.00 |
| Jun 1, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | SELL | 16,687 | $22.74 | $379.5K |
| Jun 1, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | M | 13,512 | $3.84 | $51.9K |
| Jun 1, 2026 | Pena Luis C. | President & CEO | SELL | 16,787 | $22.74 | $381.7K |
| May 28, 2026 | Carver Kyle | Chief Financial Officer | M | 15,000 | $2.99 | $44.9K |
| May 28, 2026 | Moss Gregory S. | Chief Business & Legal Officer | M | 14,223 | $1.71 | $24.3K |
| May 28, 2026 | Carver Kyle | Chief Financial Officer | SELL | 18,175 | $22.84 | $415.1K |
| May 28, 2026 | Carver Kyle | Chief Financial Officer | M | 15,000 | $0.00 | $0.00 |
| May 28, 2026 | Moss Gregory S. | Chief Business & Legal Officer | SELL | 14,223 | $22.83 | $324.7K |
| May 28, 2026 | Moss Gregory S. | Chief Business & Legal Officer | M | 14,223 | $0.00 | $0.00 |
| Apr 16, 2026 | Carver Kyle | Chief Financial Officer | A | 98,946 | $0.00 | $0.00 |
| Apr 16, 2026 | Pena Luis C. | President & CEO | A | 291,420 | $0.00 | $0.00 |
| Apr 16, 2026 | Moss Gregory S. | Chief Business & Legal Officer | A | 115,279 | $0.00 | $0.00 |
| Apr 16, 2026 | Bauer Eugene | Chief Medical Officer | A | 51,117 | $0.00 | $0.00 |
| Apr 16, 2026 | Drew Janice Suzann | Chief of Dev. Operations | A | 73,892 | $0.00 | $0.00 |
| Apr 16, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | A | 69,315 | $0.00 | $0.00 |
| Feb 17, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | A | 35,868 | $27.88 | $1000.0K |
9 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 6 neutral. Avg impact: 4.2/10.
BEARISH
144
5/10
Gregory S. Moss, an officer of Evommune, filed a Form 144 on May 28, 2026, indicating intent to sell
Jun 5, 2026
BEARISH
CLUSTER
5/10
Three top executives at Evommune (CEO, CFO, CLO) sold a combined $1.12M in open-market sales over a
Jun 4, 2026
NEUTRAL
144
3/10
Director David E. Cohen filed a Form 144 notice of intent to sell 9,258 shares of Evommune (EVMN) co
Jun 2, 2026
NEUTRAL
CLUSTER
3/10
CFO and Chief Business & Legal Officer sold a combined $740K in open-market sales on May 28, 2026, f
Jun 2, 2026
NEUTRAL
EFFECT
4/10
Evommune's S-1 registration has become effective, allowing for the resale of 4.49 million shares by
Apr 27, 2026
NEUTRAL
DEFA14A
3/10
Evommune, Inc. filed a DEFA14A proxy statement for its 2026 annual meeting, where shareholders will
Apr 21, 2026
NEUTRAL
S-1
4/10
This S-1 filing is a resale registration statement for 4.49 million shares of Evommune (EVMN) being
Apr 17, 2026
NEUTRAL
8-K
3/10
Evommune hosted a webcast on April 13, 2026, highlighting its EVO756 program targeting MRGPRX2 for m
Apr 13, 2026
BULLISH
8-K
8/10
Evommune reported positive Phase 2a data for EVO301 in atopic dermatitis and advanced its EVO756 pro
Mar 5, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (94% buy). Based on 17 analysts: 7 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$52.25 mean target
+162.3% upside
Strong Buy (1.20)
$50.00 Low
$55.00 High
| Metric | Value |
|---|---|
| Current Price | $19.92 |
| Target Low | $50.00 |
| Target Mean | $52.25 |
| Target Median | $52.00 |
| Target High | $55.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.20) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.67 | $-0.76 | $-0.61 | — | +2.2% | 5↑ 2↓ | $0.0B | — | 8 |
| Next Q 2026-09-30 |
$-0.69 | $-0.90 | $-0.18 | 91.5% | -4.9% | 3↑ 3↓ | $0.0B | -70.9% | 8 |
| Current FY 2026-12-31 |
$-2.75 | $-3.30 | $-2.09 | 75.5% | +14.4% | 5↑ 2↓ | $0.0B | -48.8% | 8 |
| Next FY 2027-12-31 |
$-3.33 | $-4.83 | $-2.48 | -21.3% | +1.0% | 4↑ 2↓ | $0.0B | -88.4% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.674 | |
| 7d ago | $-0.677 | +0.004 |
| 30d ago | $-0.689 | +0.015 |
| 60d ago | $-0.687 | +0.013 |
| 90d ago | $-0.603 | -0.071 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 11, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Apr 10, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| Mar 18, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 18, 2026 | Clear Street | INITIATE | — | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 22, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Jan 8, 2026 | Raymond James | INITIATE | — | Strong Buy |
| Jan 6, 2026 | HC Wainwright & Co. | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 20, 2026
Clinical Trial
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Phase Phase 2 — COMPLETED
May 7, 2026
short_interest
FTD: EVMN — 23,803 shares ($0.6M) failed to deliver
Settlement: 20260507, Price: $23.83, FTD Value: $567,225.49, EVOMMUNE INC COM
May 6, 2026
short_interest
FTD: EVMN — 22,951 shares ($0.6M) failed to deliver
Settlement: 20260506, Price: $24.16, FTD Value: $554,496.16, EVOMMUNE INC COM
Mar 24, 2026
short_interest
FTD: EVMN — 77,091 shares ($1.8M) failed to deliver
Settlement: 20260324, Price: $23.45, FTD Value: $1,807,783.95, EVOMMUNE INC COM
Mar 23, 2026
short_interest
FTD: EVMN — 75,985 shares ($1.8M) failed to deliver
Settlement: 20260323, Price: $23.33, FTD Value: $1,772,730.05, EVOMMUNE INC COM
Feb 11, 2026
short_interest
FTD: EVMN — 25,444 shares ($0.7M) failed to deliver
Settlement: 20260211, Price: $29.03, FTD Value: $738,639.32, EVOMMUNE INC COM